Aclaris Therapeutics (ACRS) IPO Prices at $11, Well Below Expected Range

Aclaris Therapeutics (NASDAQ: ACRS) priced its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share, below the expected $14-$16 range. The shares are expected to begin trading today on NASDAQ under the ticker symbol "ACRS".

Jefferies LLC and Citigroup Global Markets Inc. are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. is acting as a co-manager.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania.

You May Also Be Interested In

• Goldman, BofA vie to manage Anthropic employee wealth post-IPO - report
• Exclusive-Silver Lake, Intel-backed Altera prepares IPO that could raise over $2 billion as early as 2026, sources say
• Bernstein SocGen: 'BASF SE (BAS:GR) (BASFY) would be the greatest beneficiary'